PMID- 24295649
OWN - NLM
STAT- MEDLINE
DCOM- 20141001
LR  - 20151119
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 18
IP  - 1
DP  - 2014 Jan
TI  - Robinin modulates TLR/NF-kappaB signaling pathway in oxidized LDL induced human 
      peripheral blood mononuclear cells.
PG  - 191-7
LID - S1567-5769(13)00474-8 [pii]
LID - 10.1016/j.intimp.2013.11.023 [doi]
AB  - This study was designed to investigate whether robinin administration modulates 
      toll-like receptor (TLR) and nuclear factor-kappa B (NF-kappaB) signaling pathway in 
      oxidized LDL induced human peripheral blood mononuclear cells (hPBMCs). The 
      hPBMCs were isolated from healthy human volunteers and the cells were cultured in 
      collagen coated plates at 37 degrees C with 5% CO2 and RPMI as culture medium and were 
      grouped as follows: Group I - control, group II - OxLDL treated and group III - 
      OxLDL+robinin (6mug/ml). We measured mRNA expression of TLR2 and TLR4 by 
      reverse-transcriptase polymerase chain reaction (RT-PCR) and NF-kappaB transcription 
      factor assay (ELISA), and western blotting studies were done for knowing 
      expression of monocyte chemotactic protein-1 (MCP 1), tumor necrosis factor-alpha 
      (TNF-alpha) interleukin-6 (IL-6) and vascular cell adhesion molecule 1 (VCAM-1). The 
      result indicates that OxLDL that induces hPBMCs showed an upregulated expression 
      of TLR2, TLR4, NF-kappaB, pro-inflammatory cytokines and VCAM-1. Robinin inhibited 
      the ox-LDL induced TLR2 and TLR4 expression at mRNA level and inhibited the 
      translocation of NF-kappaB p65 by modulating the TLR-NF-kappaB signaling pathway thereby 
      inhibiting cytokine production and down regulated inflammatory enzymes like 
      cyclooxygenase (COX), lipoxygenase (LOX), nitric oxide synthase (NOS) and 
      prostaglandin E2 (PGE2), thus having protective effect against the ox-LDL induced 
      inflammation stress in hPBMCs by inhibiting TLR4-NF-kappaB signaling pathway.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Janeesh, P A
AU  - Janeesh PA
AD  - Department of Biochemistry, University of Kerala, Thiruvananthapuram, Kariavattom 
      Campus, 695 581 Kerala, India.
FAU - Sasikala, V
AU  - Sasikala V
AD  - Department of Biochemistry, University of Kerala, Thiruvananthapuram, Kariavattom 
      Campus, 695 581 Kerala, India.
FAU - Dhanya, C R
AU  - Dhanya CR
AD  - Department of Biochemistry, University of Kerala, Thiruvananthapuram, Kariavattom 
      Campus, 695 581 Kerala, India.
FAU - Abraham, Annie
AU  - Abraham A
AD  - Department of Biochemistry, University of Kerala, Thiruvananthapuram, Kariavattom 
      Campus, 695 581 Kerala, India. Electronic address: annieab2001@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131202
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Cytokines)
RN  - 0 (Flavonoids)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (NF-kappa B)
RN  - 0 (TLR2 protein, human)
RN  - 0 (TLR4 protein, human)
RN  - 0 (Toll-Like Receptor 2)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 0 (oxidized low density lipoprotein)
RN  - 75RT1VGM60 (robinin)
SB  - IM
MH  - Cells, Cultured
MH  - Cytokines/metabolism
MH  - Cytoprotection
MH  - Flavonoids/*pharmacology
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Leukocytes, Mononuclear/*drug effects/immunology
MH  - Lipoproteins, LDL/immunology
MH  - NF-kappa B/genetics/*metabolism
MH  - Oxidative Stress/drug effects
MH  - Signal Transduction/drug effects
MH  - Toll-Like Receptor 2/genetics/*metabolism
MH  - Toll-Like Receptor 4/genetics/*metabolism
MH  - Vascular Cell Adhesion Molecule-1/metabolism
OTO - NOTNLM
OT  - Inflammatory marker enzymes
OT  - Oxidized LDL
OT  - Robinin
OT  - TLR-NF-kappaB signaling pathway
OT  - hPBMCs
EDAT- 2013/12/04 06:00
MHDA- 2014/10/02 06:00
CRDT- 2013/12/04 06:00
PHST- 2013/08/16 00:00 [received]
PHST- 2013/11/19 00:00 [revised]
PHST- 2013/11/20 00:00 [accepted]
PHST- 2013/12/04 06:00 [entrez]
PHST- 2013/12/04 06:00 [pubmed]
PHST- 2014/10/02 06:00 [medline]
AID - S1567-5769(13)00474-8 [pii]
AID - 10.1016/j.intimp.2013.11.023 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2014 Jan;18(1):191-7. doi: 10.1016/j.intimp.2013.11.023. 
      Epub 2013 Dec 2.